Personal information

Emails & domains

Verified email domains

Websites & social links

Lab Webpage

Other IDs

Scopus Author ID: 57209003282

Activities

Collapse all

Employment (5)

Monash University: Melbourne, VIC, AU

2020-04-01 to 2024-12-31 | Lab Head & NHF Future Leader (Drug Discovery Biology )
Employment
Source: Self-asserted source
Chengxue Qin

Baker Heart and Diabetes Institute: Melbourne, AU

2017-07 to 2020-03 | Group Leader Drug Discovery & Baker Fellow
Employment
Source: Self-asserted source
Chengxue Qin

Baker Heart and Diabetes Institute: Melbourne, AU

2016-01 to 2017-06 | Senior Research Officer (Heart Failure Pharmacology)
Employment
Source: Self-asserted source
Chengxue Qin

Baker Heart and Diabetes Institute: Melbourne, AU

2011-02 to 2015-12 | Research Officer (Heart Failure Pharmacology)
Employment
Source: Self-asserted source
Chengxue Qin

University of Melbourne: Melbourne, AU

2010-01 to 2011-01 | Research Fellow (Department of Pharmacology and Therapeutic)
Employment
Source: Self-asserted source
Chengxue Qin

Education and qualifications (3)

University of Melbourne: Melbourne, AU

2006 to 2010 | Doctor of Philosophy (Department of Pharmacology and School of Chemistry)
Education
Source: Self-asserted source
Chengxue Qin

University of Melbourne: Melbourne, AU

2005 to 2005 | Bachelor of Science (Hons) (Department of Pharmacology)
Education
Source: Self-asserted source
Chengxue Qin

University of Melbourne: Melbourne, AU

2002 to 2004 | Bachelor of Biomedical Science (Drug Discovery (Pharmacology and Medicinal Chemistry))
Education
Source: Self-asserted source
Chengxue Qin

Professional activities (7)

High Blood Pressure Research Council of Australia: Melbourne, Victoria, AU

2023-12 | High Blood Pressure Jaye Chin-Dusting Award
Distinction
Source: Self-asserted source
Chengxue Qin

MIPS Future Research Leader Award: Melbourne, VIC, AU

2020 | MIPS Future Research Leader Award
Distinction
Source: Self-asserted source
Chengxue Qin

American Heart Association: Dallas, US

2020 | Paul Dudley White International Scholar Award -AHA
Distinction
Source: Self-asserted source
Chengxue Qin

Asian-Australian Leadership Award: Melbourne, VIC, AU

2019-11-15 | Asian-Australian Leadership Award
Distinction
Source: Self-asserted source
Chengxue Qin

International Society for Heart Research: Durham, North Carolina, US

2017 | International Society for Heart Research-Early Career Investigator Award
Distinction
Source: Self-asserted source
Chengxue Qin

Cardiac Society of Australia and New Zealand: Sydney, New South Wales, AU

2016 | Cardiac Society of Australia and New Zealand-Ralph Reader Award
Distinction
Source: Self-asserted source
Chengxue Qin

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists: Adelaide, AU

2015-12-01 | British Pharmacological Society (BPS)/ASCEPT Outstanding Early Career Investigator Award
Distinction
Source: Self-asserted source
Chengxue Qin

Funding (40)

Development of Innovative Small Molecules for Therapeutic Intervention for Pulmonary Arterial Hypertension

2025-01 to 2026-12 | Grant
National Health and Medical Research Council (Canberra, AU)
Source: Self-asserted source
Chengxue Qin

Building Robust Translational Research Networks in the Asia-Pacific Region

2025-01 to 2025-12 | Grant
National Heart Foundation of Australia (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Development of innovative Small Molecules for Therapeutic Intervention for Pulmonary Arteria Hypertension

2024-12 to 2025-12 | Grant
Therapeutic Innovation Australia (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Functional assays and activity assessment studies

2024-11 to 2025-12 | Contract
Thetis Pharma Pty Ltd (Ridgefield, US)
Source: Self-asserted source
Chengxue Qin

Development of a New Class of GPCR Biased Agonists for Heart Failure with Preserved Ejection Fraction

2024-10 to 2025-12 | Grant
Medchem Australia (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

 Novel disease-modifying approach to treat pulmonary arterial hypertension

2024 to 2026 | Grant
BioCurate's Proof-of-Concept (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Resolving inflammation to treat vessel stiffness in diabetes

2024 to 2025 | Grant
Diabetes Australia (Canberra, Australian Capital Territory, AU)
Source: Self-asserted source
Chengxue Qin

Monash research talent accelerator fellow

2023-01 to 2024-12 | Grant
Monash University (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Advancing preclinical development of novel GPCR-targeted therapeutics for heart failure

2023 to 2025 | Grant
Medical Research Future Fund (Canberra, AU)
Source: Self-asserted source
Chengxue Qin

Endothelial Cells: an underappreciated therapeutic target in HFpEF

2023 to 2024 | Grant
NHF Vanguard (Canberra, AU)
Source: Self-asserted source
Chengxue Qin

Novel disease-modifying approach to treat pulmonary arterial hypertension

2023 to 2024 | Grant
Therapetuic innovation Aus (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Novel pro-resolving GPCR signalling platform

2023 to 2024 | Grant
Monash Talent Accelerator (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Post-MI therapeutic regulatory advice

2023 to 2024 | Grant
Australian Stroke and Heart Research Accelerator (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Development of a New Class of Formyl Peptide Receptor 1 (FPR1) Biased Agonists for the Treatment of Myocardial Infarction

2022-12-14 to present | Grant
National Health and Medical Research Council (Canberra, AU)
URL: https://app.dimensions.ai/details/grant/grant.13300931
GRANT_NUMBER:

2022040
Source: Self-asserted source
Chengxue Qin via DimensionsWizard

Bridge and BridgeTech industry Fellowship

2022-08 to 2022-12 | Salary award
MTP Connect (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Developing novel pro-resolving medicines to treat vulnerable atherosclerotic plaques

2022 to 2022 | Grant
CAD Frontier Catalysts (NSW, AU)
Source: Self-asserted source
Chengxue Qin

Resolving inflammation to treat diabetic vascular remodelling

2022 to 2022 | Grant
Diabetes Australia (Canberra, Australian Capital Territory, AU)
Source: Self-asserted source
Chengxue Qin

A novel approach to treat lower extremity peripheral artery disease

2021 to 2024 | Grant
National Nature Science (Beijing, CN)
Source: Self-asserted source
Chengxue Qin

Development of novel FPR2 agonists to treat pulmonary arterial hypertension

2021 to 2022 | Grant
MIPS Commercialization incubator program 2021 (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Discovery of new drugs to treat pulmonary hypertension

2021 to 2022 | Grant
National drug discovery centre (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension

2021 to 2022 | Grant
Therapeutic Innovation Australia (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Targeting the cause, not the symptom: a novel approach to treat stiff vessels in high blood pressure

2021 to 2022 | Grant
Cass Foundation (VIC, VIC, AU)
Source: Self-asserted source
Chengxue Qin

QuantStudio 7 Flex Real-Time PCR System

2021 to 2021 | Grant
National Health and Medical Research Council (ACT, ACT, AU)
Source: Self-asserted source
Chengxue Qin

Formyl Peptide Receptor Agonist as Novel Therapy for Hypertension

2020-04-01 to present | Grant
National Heart Foundation of Australia (Melbourne, AU)
URL: https://app.dimensions.ai/details/grant/grant.13893120
GRANT_NUMBER:

102885
Source: Self-asserted source
Chengxue Qin via DimensionsWizard

Therapeutic Targeting of Formyl Peptide Receptors to Treat Cardiovascular Disease

2020-04-01 to present | Grant
National Heart Foundation of Australia (Melbourne, AU)
URL: https://app.dimensions.ai/details/grant/grant.13893112
GRANT_NUMBER:

102787
Source: Self-asserted source
Chengxue Qin via DimensionsWizard

Targeting Formyl peptide receptors to treat cardiovascular Disease

2020-04 to 2024-12 | Salary award
National Heart Foundation of Australia (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Exploiting Biased Agonists of Formyl Peptide Receptors as Pharmacotherapy for Pulmonary Hypertension: simultaneous targeting of vascular function and remodelling

2019-12-07 to present | Grant
National Health and Medical Research Council (Canberra, AU)
URL: https://app.dimensions.ai/details/grant/grant.8853744
GRANT_NUMBER:

1187989
Source: Self-asserted source
Chengxue Qin via DimensionsWizard

Prodrug Development of Biased N-Alkylpyridazinones for the Acute Intravenous Treatment of Myocardial Ischaemia-Reperfusion Injury

2019-01-01 to present | Grant
National Health and Medical Research Council (Canberra, AU)
URL: https://app.dimensions.ai/details/grant/grant.7877819
GRANT_NUMBER: 1155527
Source: Self-asserted source
Chengxue Qin via DimensionsWizard

Regulatory T Cells and Kidney Disease Progression in T1D

2019 to 2021 | Grant
Juvenile Diabetes Research Foundation Australia (NSW, NSW, AU)
Source: Self-asserted source
Chengxue Qin

Novel approach to deliver drugs to treat diabetic ulcer

2018 to 2021 | Grant
Spring city 5150 entrepreneur Talent (Jinan, CN)
Source: Self-asserted source
Chengxue Qin

Inhaled formyl peptide receptor agonists for pulmonary fibrosis

2018 to 2019 | Grant
The Inaugural Victoria Medical Acceleration Fund from Victoria Government (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Discovering new drugs to treat diabetes-induced cardiovascular complications

2018 to 2018 | Grant
Diabetes Australia (ACT, ACT, AU)
Source: Self-asserted source
Chengxue Qin

Baker Fellow

2017-07 to 2020-03 | Salary award
Baker Heart and Diabetes Institute (Melbourne, AU)
Source: Self-asserted source
Chengxue Qin

Formyl Peptide Receptors (FPRs): A novel approach to treat hypertension

2017 to 2018 | Grant
Baker IDI Heart and Diabetes Institute (VIC, VIC, AU)
Source: Self-asserted source
Chengxue Qin

Novel therapeutic approach to treat diabetic ulcer

2016 to 2018 | Grant
Hai You Talent Program (Jinan, CN)
Source: Self-asserted source
Chengxue Qin

Preventing diabetes-induced heart failure with a natural inflammatory protein

2015 to 2015 | Grant
Cass Foundation (VIC, VIC, AU)
Source: Self-asserted source
Chengxue Qin

Targeting myocardial infarction with novel formyl peptide receptor mimetics

2015 to 2015 | Grant
Baker IDI Heart and Diabetes Institute (VIC, VIC, AU)
Source: Self-asserted source
Chengxue Qin

Equipment grant for the Working Heart Isolated Perfusion system from ADInstruments

2014 to 2014 | Grant
The Joe White Bequest (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Targeting myocardial infarction with novel Annexin-A1 mimetics

2014 to 2014 | Grant
Baker IDI Heart and Diabetes Institute (VIC, VIC, AU)
Source: Self-asserted source
Chengxue Qin

Evaluating the role of O-GlcNAcylation on the pathogenesis of abnormal cardiac function in diabetes.

2012 to 2015 | Grant
The James and Elsie Borrowman Trust (VIC, AU)
Source: Self-asserted source
Chengxue Qin

Works (50 of 79)

Items per page:
Page 1 of 2

Decoding metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis (In press)

Science
2025 | Journal article
Contributors: Chuanshuan Ma; Kui Cai; Lulu Guo; Xuemei Wang; Lin Lv; Chao Zhang; Jun Lin; Daolai Zhang; Chuan Ye; Tengwei Wang et al.
Source: Self-asserted source
Chengxue Qin

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), the Asia Pacific Federation of Pharmacologists (APFP) and the Australasian Pharmaceutical Science Association (APSA) Joint congress, Australia

Resolution Pharmacology: Unveiling Nature's Healing Mechanism
2024-12-04 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

Biased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists

British Journal of Pharmacology
2024-11 | Journal article | Author
DOI: 10.1111/bph.17310
Part of ISSN: 0007-1188
Part of ISSN: 1476-5381
Contributors: Cheng Peng; Elizabeth A. Vecchio; Anh T. N. Nguyen; Mia De Seram; Ruby Tang; Peter Keov; Owen Woodman; Yung‐Chih Chen; Jonathan Baell; Lauren May et al.
Source: Self-asserted source
Chengxue Qin

Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunction

Cardiovascular Diabetology
2024-11-20 | Journal article | Author
DOI: 10.1186/s12933-024-02501-x
Part of ISSN: 1475-2840
Contributors: Ting Fu; Muthukumar Mohan; Madhura Bose; Eoin Brennan; Helen Kiriazis; Minh Deo; Cameron Nowell; Catherine Godson; Mark Cooper; Peishen Zhao et al.
Source: Self-asserted source
Chengxue Qin

Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage

Cardiovascular Research
2024-09-21 | Journal article | Author
DOI: 10.1093/cvr/cvae103
Part of ISSN: 0008-6363
Part of ISSN: 1755-3245
Contributors: Jaideep Singh; Kristy Jackson; Haoyun Fang; Audrey Gumanti; Bethany Claridge; Feng Shii Tang; Helen Kiriazis; Ekaterina; Alex M Parker; Cameron Nowell et al.
Source: Self-asserted source
Chengxue Qin

12th International Conference on Annexins, Singapore

Unravelling the Annexin-A1/FPR2 Axis: Harnessing Therapeutic Potential in Cardiopulmonary Pathologies
2024-06-28 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

Formyl peptide receptor 1 mitigates colon inflammation and maintains mucosal homeostasis through the inhibition of CREB-C/EBPβ-S100a8 signaling.

Mucosal immunology
2024-04-15 | Journal article
DOI: 10.1016/j.mucimm.2024.04.001
PMID: 38614323
Contributors: Li T; Zhou X; Zhang Q; Miao Q; Woodman OL; Chen Y; Qin C
Source: Self-asserted source
Chengxue Qin

The pro‐resolving mediator, annexinA1 vregulates blood pressure, and age‐associated changes in cardiovascular function and remodeling

The FASEB Journal
2024-02-15 | Journal article | Author
DOI: 10.1096/fj.202301802r
Part of ISSN: 0892-6638
Part of ISSN: 1530-6860
Contributors: Jaideep Singh; Kristy Jackson; Feng Shii Tang; Ting Fu; Cameron Nowell; Ekaterina; Helen Kiriazis; Rebecca Ritchie; Geoffrey Head; Owen Woodman et al.
Source: Self-asserted source
Chengxue Qin

Australia Cardiovascular Alliance Precision Medicine Flagship Symposium, Australia

Pro-resolving GPCR: Emerging Druggable Targets for Cardiovascular Medicine
2023-12-08 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists.

European journal of medicinal chemistry
2023-11-27 | Journal article
DOI: 10.1016/j.ejmech.2023.115989
PMID: 38199163
Contributors: Yi X; Tran E; Odiba JO; Qin CX; Ritchie RH; Baell JB
Source: Self-asserted source
Chengxue Qin

MRFF Cardiovascular Health Mission Showcase, Australia

Pro-resolving Medicine: Novel Approaches to Treat Cardiopulmonary Diseases
2023-09-13 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

The small-molecule formyl peptide receptor biased agonist, compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices.

British journal of pharmacology
2023-09-01 | Journal article | Author
DOI: 10.1111/bph.16231
PMID: 37658546
Contributors: William Studley; Lamanna E; Martin KA; Claudia Nold-Petry; Simon Royce; Owen Woodman; Rebecca Ritchie; Chengxue Qin; Jane Elizabeth Bourke
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 2)‎

Novel AT2R agonist, β-Pro 7Ang III, is cardio- and vaso-protective in diabetic spontaneously hypertensive rats.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2023-08-01 | Journal article
DOI: 10.1016/j.biopha.2023.115238
PMID: 37536036
Contributors: Li M; Nguyen L; Ferens D; Spizzo I; Wang Y; Denton KM; Del Borgo M; Ketav Kulkarni; Mibel Aguilar; Qin CH et al.
Source: Self-asserted source
Chengxue Qin

Targeting G protein-coupled receptors for heart failure treatment.

British journal of pharmacology
2023-04-24 | Journal article | Author
DOI: 10.1111/bph.16099
PMID: 37095602
Contributors: Bui San Thai; Chia LY; Anh Thi Ngoc Nguyen; Chengxue Qin; Rebecca Ritchie; Dana Hutchinson; Andrew Kompa; White PJ; Lauren May
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 2)‎

Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2023-03-28 | Journal article
DOI: 10.1016/j.biopha.2023.114578
PMID: 36996678
Contributors: Chen Huei Leo; Ou JLM; Eng Shi Ong; Qin CX; Ritchie RH; Parry LJ; Ng HH
Source: Self-asserted source
Chengxue Qin

Endothelium-dependent relaxation is impaired in Schlager hypertensive (BPH/2J) mice by region-specific mechanisms in conductance and resistance arteries.

Life sciences
2023-03-05 | Journal article
DOI: 10.1016/j.lfs.2023.121542
PMID: 36871935
Contributors: Jelinic M; Jackson KL; O'Sullivan K; Singh J; Giddy T; Deo M; Parry LJ; Ritchie RH; Woodman OL; Head GA et al.
Source: Self-asserted source
Chengxue Qin

A high-sucrose diet exacerbates the left ventricular phenotype in a high fat-fed streptozotocin rat model of diabetic cardiomyopathy.

American journal of physiology. Heart and circulatory physiology
2023-01-06 | Journal article
DOI: 10.1152/ajpheart.00390.2022
PMID: 36607798
Contributors: Velagic A; Mandy Li; Deo M; Li JC; Kiriazis H; Donner, Daniel G.; Anderson D; De Blasio MJ; Owen Woodman; Barbara Kemp-Harper et al.
Source: Self-asserted source
Chengxue Qin

The Australasian Society of Clinical and Experimental Pharmacologist and Toxicologists, Australia

Innovative approaches to resolve inflammation in the heart and vasculature
2022-12-01 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

Baker Heart and Diabetes Institute EMCR symposium, Australia

Pro-resolving GPCRs for Therapeutic Innovation: opportunities and challenges for novel cardiovascular medicine
2022-09-26 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35.

British journal of pharmacology
2022-07-29 | Journal article | Author
DOI: 10.1111/bph.15919
PMID: 35797341
PMC: PMC9545948
Contributors: Chengxue Qin; Norling LV; Vecchio EA; Brennan EP; Lauren May; Wootten D; Godson C; Mauro Perretti; Rebecca Ritchie
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 2)‎

Novel strategies to promote resolution of inflammation to treat lower extremity artery disease.

Current opinion in pharmacology
2022-07-05 | Journal article
DOI: 10.1016/j.coph.2022.102263
PMID: 35802962
Contributors: Zhang Q; Li F; Ritchie RH; Woodman OL; Zhou X; Qin CX
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 2)‎

Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance.

British journal of pharmacology
2022-04-26 | Journal article | Author
DOI: 10.1111/bph.15849
PMID: 35365882
PMC: PMC9540873
Contributors: Anida Velagic; Li JC; Chengxue Qin; Li M; Deo M; Sarah Arwen Marshall; Dovile Anderson; Owen Woodman; Horowitz JD; Kemp-Harper BK et al.
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 2)‎

Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.

Acta pharmacologica Sinica
2022-01-19 | Journal article
DOI: 10.1038/s41401-021-00835-w
PMID: 35046517
PMC: PMC8767044
Contributors: Zhang FS; He QZ; Qin CH; Little PJ; Jianping Weng; Suowen Xu
Source: Self-asserted source
Chengxue Qin

Antibiotic-chemoattractants enhance neutrophil clearance of Staphylococcus aureus.

Nature communications
2021-10-25 | Journal article | Author
DOI: 10.1038/s41467-021-26244-5
PMID: 34697316
PMC: PMC8546149
Contributors: Jennifer Payne; Tailhades J; Felix Ellett; Xenia Kostoulias; Alex Fulcher; Fu T; Leung R; Stephanie Louch; Amy Tran; Weber SA et al.
Source: Self-asserted source
Chengxue Qin

Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019.

Hypertension (Dallas, Tex. : 1979)
2021-09-27 | Journal article
DOI: 10.1161/hypertensionaha.120.14525
PMID: 34565184
Contributors: Tara Elizabeth Scott; Qin CX; Grant Drummond; Adrian Hobbs; Kemp-Harper BK
Source: Self-asserted source
Chengxue Qin

Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress.

Clinical science (London, England : 1979)
2021-09-01 | Journal article
DOI: 10.1042/cs20210628
PMID: 34427662
PMC: PMC8436265
Contributors: Dr Sherouk Fouda; Khan A; Stanley Chan; Ali Mahzari; Zhou X; Qin CX; Ross Vlahos; Jiming Ye
Source: Self-asserted source
Chengxue Qin

Huangbai Liniment Ameliorates Skin Inflammation in Atopic Dermatitis.

Frontiers in pharmacology
2021-08-31 | Journal article
DOI: 10.3389/fphar.2021.726035
PMID: 34531749
PMC: PMC8438128
Contributors: Zheng T; Fan M; Wei Y; Feng J; Pengcheng Zhou; Sun X; Xue A; Qin CX; Di Yu
Source: Self-asserted source
Chengxue Qin

Corrigendum: Characterising an Alternative Murine Model of Diabetic Cardiomyopathy.

Frontiers in physiology
2021-08-19 | Journal article
DOI: 10.3389/fphys.2021.734320
PMID: 34489742
PMC: PMC8417435
Contributors: Tate M; Prakoso D; Willis AM; Peng C; Deo M; Qin CX; Walsh JL; Nash DM; Cohen CD; Rofe AK et al.
Source: Self-asserted source
Chengxue Qin

Diabetes Attenuates the Contribution of Endogenous Nitric Oxide but Not Nitroxyl to Endothelium Dependent Relaxation of Rat Carotid Arteries.

Frontiers in pharmacology
2021-01-21 | Journal article
DOI: 10.3389/fphar.2020.585740
PMID: 33716721
PMC: PMC7944142
Contributors: Li JC; Velagic A; Qin CX; Li M; Leo CH; Kemp-Harper BK; Ritchie RH; Woodman OL
Source: Self-asserted source
Chengxue Qin

Silk fibroin/poly-(L-lactide-co-caprolactone) nanofiber scaffolds loaded with Huangbai Liniment to accelerate diabetic wound healing.

Colloids and surfaces. B, Biointerfaces
2021-01-05 | Journal article
DOI: 10.1016/j.colsurfb.2021.111557
PMID: 33434880
Contributors: Xu X; Wang X; Qin C; Atta ur Rehman Khan; Zhang W; Mo X
Source: Self-asserted source
Chengxue Qin

Annexin-A1 deficiency exacerbates pathological remodelling of the mesenteric vasculature in insulin-resistant, but not insulin-deficient, mice

British Journal of Pharmacology
2020 | Journal article
DOI: 10.1111/bph.14927
EID:

2-s2.0-85079402611

Part of ISBN:

14765381 00071188
Contributors: Jelinic, M.; Kahlberg, N.; Leo, C.H.; Ng, H.H.; Rosli, S.; Deo, M.; Li, M.; Finlayson, S.; Walsh, J.; Parry, L.J. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Nitric Oxide Resistance, Induced in the Myocardium by Diabetes, Is Circumvented by the Nitric Oxide Redox Sibling, Nitroxyl

Antioxidants & redox signaling
2020 | Journal article
DOI: 10.1089/ars.2018.7706
EID:

2-s2.0-85076386879

Part of ISBN:

15577716
Contributors: Qin, C.X.; Anthonisz, J.; Leo, C.H.; Kahlberg, N.; Velagic, A.; Li, M.; Jap, E.; Woodman, O.L.; Parry, L.J.; Horowitz, J.D. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights

British Journal of Pharmacology
2020 | Journal article
DOI: 10.1111/bph.14858
EID:

2-s2.0-85074924573

Part of ISBN:

14765381 00071188
Contributors: Leo, C.H.; Ng, H.H.; Marshall, S.A.; Jelinic, M.; Rupasinghe, T.; Qin, C.; Roessner, U.; Ritchie, R.H.; Tare, M.; Parry, L.J.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier
grade
Preferred source (of 2)‎

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.

Frontiers in pharmacology
2020-12-03 | Journal article
DOI: 10.3389/fphar.2020.603926
PMID: 33343375
PMC: PMC7745178
Contributors: Peng C; Stewart AG; Woodman OL; Ritchie RH; Qin CX
Source: Self-asserted source
Chengxue Qin

Editorial: Inflammation in Cardiovascular Diseases: Role of the Endothelium and Emerging Therapeutics.

Frontiers in pharmacology
2020-11-17 | Journal article
DOI: 10.3389/fphar.2020.614387
PMID: 33364970
PMC: PMC7751751
Contributors: Qin CX; Woodman OL; Leo CH
Source: Self-asserted source
Chengxue Qin

Current state and future perspective of cardiovascular medicines derived from natural products.

Pharmacology & therapeutics
2020-10-09 | Journal article
DOI: 10.1016/j.pharmthera.2020.107698
PMID: 33039419
Contributors: Zhao C; Li S; Zhang J; Huang Y; Zhang L; Zhao F; Du X; Hou J; Zhang T; Shi C et al.
Source: Self-asserted source
Chengxue Qin

Nitroxyl: A Novel Strategy to Circumvent Diabetes Associated Impairments in Nitric Oxide Signaling.

Frontiers in pharmacology
2020-05-19 | Journal article
DOI: 10.3389/fphar.2020.00727
PMID: 32508651
PMC: PMC7248192
Contributors: Velagic A; Qin C; Woodman OL; Horowitz JD; Ritchie RH; Kemp-Harper BK
Source: Self-asserted source
Chengxue Qin

The Novel Small-molecule Annexin-A1 Mimetic, Compound 17b, Elicits Vasoprotective Actions in Streptozotocin-induced Diabetic Mice.

International journal of molecular sciences
2020-02-18 | Journal article | Author
DOI: 10.3390/ijms21041384
PMID: 32085666
PMC: PMC7073122
Contributors: Sarah Arwen Marshall; Chengxue Qin; Jelinic M; O'Sullivan K; Deo M; Walsh J; Mandy Li; Parry LJ; Ritchie RH; Chen Huei Leo
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 4)‎

Therapeutic Potential of Lipoxin A<sub>4</sub> in Chronic Inflammation: Focus on Cardiometabolic Disease.

ACS pharmacology & translational science
2020-01-17 | Journal article
DOI: 10.1021/acsptsci.9b00097
PMID: 32259087
PMC: PMC7088989
Contributors: Fu T; Muthukumar Mohan; Eoin Brennan; Woodman OL; Catherine Godson; Kantharidis P; Ritchie RH; Qin CX
Source: Self-asserted source
Chengxue Qin
grade
Preferred source (of 2)‎

Cardioprotective actions of the annexin-A1 N-terminal peptide, AC<inf>2-26</inf>, against myocardial infarction

Frontiers in Pharmacology
2019 | Journal article
DOI: 10.3389/fphar.2019.00269
EID:

2-s2.0-85066044619

Part of ISBN:

16639812
Contributors: Qin, C.X.; Rosli, S.; Deo, M.; Cao, N.; Walsh, J.; Tate, M.; Alexander, A.E.; Donner, D.; Horlock, D.; Li, R. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Characterising an Alternative Murine Model of Diabetic Cardiomyopathy

Frontiers in Physiology
2019 | Journal article
DOI: 10.3389/fphys.2019.01395
EID:

2-s2.0-85076006941

Part of ISBN:

1664042X
Contributors: Tate, M.; Prakoso, D.; Willis, A.M.; Peng, C.; Deo, M.; Qin, C.X.; Walsh, J.L.; Nash, D.M.; Cohen, C.D.; Rofe, A.K. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Novel Role for the AnxA1-Fpr2/ALX Signaling Axis as a Key Regulator of Platelet Function to Promote Resolution of Inflammation

Circulation
2019 | Journal article
DOI: 10.1161/CIRCULATIONAHA.118.039345
EID:

2-s2.0-85070182752

Part of ISBN:

15244539 00097322
Contributors: Senchenkova, E.Y.; Ansari, J.; Becker, F.; Vital, S.A.; Al-Yafeai, Z.; Sparkenbaugh, E.M.; Pawlinski, R.; Stokes, K.Y.; Carroll, J.L.; Dragoi, A.-M. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Substituted Pyridazin-3(2 H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists

Journal of Medicinal Chemistry
2019 | Journal article
DOI: 10.1021/acs.jmedchem.8b01912
EID:

2-s2.0-85066051060

Part of ISBN:

15204804 00222623
Contributors: Deora, G.S.; Qin, C.X.; Vecchio, E.A.; Debono, A.J.; Priebbenow, D.L.; Brady, R.M.; Beveridge, J.; Teguh, S.C.; Deo, M.; May, L.T. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier
grade
Preferred source (of 2)‎

Queenstown Molecular Biology Meeting, New Zealand

Exploring receptor bias for the diseased heart
2019-09 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin

SAT-105 GLUCOSE-DEPENDENT MITOCHONDRIAL ALTERATIONS IN DIABETIC KIDNEY DISEASE

Kidney International Reports
2019-07 | Journal article
DOI: 10.1016/j.ekir.2019.05.133
Part of ISSN: 2468-0249
Contributors: C. GRANATA; V. Thallas-Bonke; C.X. Qin; A. Laskowski; E. Jap; G. Ramm; M. Cooper; D. Stroud; R. Ritchie; M. Coughlan
Source: Self-asserted source
Chengxue Qin

Correspondence: Reply to 'Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury'

Nature Communications
2018 | Journal article
DOI: 10.1038/s41467-017-02656-0
EID:

2-s2.0-85041848895

Part of ISBN:

20411723
Contributors: Qin, C.X.; May, L.T.; Sexton, P.M.; DeBono, A.J.; Baell, J.B.; Christopoulos, A.; Ritchie, R.H.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia

Scientific Reports
2018 | Journal article
DOI: 10.1038/s41598-018-20703-8
EID:

2-s2.0-85041642536

Part of ISBN:

20452322
Contributors: Chandramouli, C.; Reichelt, M.E.; Curl, C.L.; Varma, U.; Bienvenu, L.A.; Koutsifeli, P.; Raaijmakers, A.J.A.; De Blasio, M.J.; Qin, C.X.; Jenkins, A.J. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Distinct contributions of hyperglycemia and high-fat feeding in metabolic syndrome-induced neuroinflammation

Journal of Neuroinflammation
2018 | Journal article
DOI: 10.1186/s12974-018-1329-8
EID:

2-s2.0-85055161096

Part of ISBN:

17422094
Contributors: Wanrooy, B.J.; Kumar, K.P.; Wen, S.W.; Qin, C.X.; Ritchie, R.H.; Wong, C.H.Y.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Erratum: Author Correction: Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo (Scientific reports (2017) 7 1 (16615))

Scientific reports
2018 | Journal article
DOI: 10.1038/s41598-018-24994-9
EID:

2-s2.0-85070652492

Part of ISBN:

20452322
Contributors: Qin, C.X.; Finlayson, S.B.; Al-Sharea, A.; Tate, M.; De Blasio, M.J.; Deo, M.; Rosli, S.; Prakoso, D.; Thomas, C.J.; Kiriazis, H. et al.
Source: Self-asserted source
Chengxue Qin via Scopus - Elsevier

Gage Symposium, Australia

Targeting formyl peptide receptor to treat cardiovascular disease
2018-04-19 | Conference abstract
Contributors: Chengxue Qin
Source: Self-asserted source
Chengxue Qin
Items per page:
Page 1 of 2

Peer review (7 reviews for 6 publications/grants)

Review activity for ACS chemical neuroscience. (1)
Review activity for ACS omega. (1)
Review activity for Cardiovascular research. (1)
Review activity for Hepatology international. (1)
Review activity for Journal of medicinal chemistry. (1)
Review activity for Pharmacology & therapeutics. (2)
How many people are using ORCID?